The Q4 2018 results from GW Pharmaceuticals (GWPH) illustrated the promise of their Epidiolex product approved for the two childhood epilepsies of Lennox-Gastaut syndrome and Dravet syndrome. As my article in January detailed, the international potential of the product has been somewhat overlooked. The product should produce sufficient revenues for the company to flourish until the promise of further pipeline candidates is resolved. Epidiolex approval for tuberous sclerosis complex could be especially important to cement the company's stock valuation. Other drugs also provide rich promise. Further determination on the pipeline should be seen